Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinyl carbamates as potent and long acting muscarinic antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 11, 2011, Pages 3457-3461

  Prat, Maria ^a   Buil, María Antonia ^a   Fernández, Maria Dolors ^b   Castro, Jordi ^a   Monleón, Juan Manuel ^a   Tort, Laia ^a   Casals, Gaspar ^a   Ferrer, Manuel ^a   Huerta, Josep Maria ^a   Espinosa, Snia ^a   López, Manuel ^a   Segarra, Victor ^a   Gavald, Amadeu ^a   Miralpeix, Montserrat ^a   Ramos, Israel ^a   Vilella, Dolors ^a   González, Marisa ^a   Córdoba, Mnica ^a   Cárdenas, Alvaro ^c   Antón, Francisca ^d   Beleta, Jorge ^a   Ryder, Hamish ^e   more..

^a RandD Centre ^*  (Spain)

^b THOMSON REUTERS   (United Kingdom)

^c UCB PHARMA   (Belgium)

^d Laboratorios Lesvi SL   (Spain)

^e CRT Discovery Laboratories   (United Kingdom)

Author keywords

(3R) Quinuclidinyl carbamates; COPD; Long acting bronchodilators; Low systemic exposure; M 3 Muscarinic antagonists

Indexed keywords

CARBAMIC ACID DERIVATIVE; IPRATROPIUM BROMIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; QUATERNARY AMMONIUM DERIVATIVE; SOLIFENACIN; TIOTROPIUM BROMIDE;

ARTICLE; BRONCHOSPASM; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; LIVER MICROSOME; LIVER MICROSOME METABOLISM; STRUCTURE ACTIVITY RELATION;

CARBAMATES; DRUG DISCOVERY; HUMANS; INHIBITORY CONCENTRATION 50; MICROSOMES, LIVER; MOLECULAR STRUCTURE; MUSCARINIC ANTAGONISTS; QUATERNARY AMMONIUM COMPOUNDS; QUINUCLIDINES; TIME FACTORS;

EID: 79956142979     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.03.096     Document Type: Article

References (27)

1. K.F. Rabe, S. Hurd, A. Anzueto, P.J. Barnes, S.A. Buist, P. Calverley, Y. Fukuchi, C. Jenkins, R. Rodriguez-Roisin, C. van Weel, and J. Zielinski Am. J. Respir. Crit. Care Med. 176 2007 532
2. A.D. Lopez, K. Shibuya, C. Rao, C.D. Mathers, A.L. Hansell, L.S. Held, V. Schmid, and S. Buist Eur. Respir. J. 27 2006 397
3. N.J. Gross, and M.S. Skorodin N. Engl. J. Med. 311 1984 421
4. N.J. Gross, and M.S. Skorodin Am. Rev. Respir. Dis. 129 1984 856
5. P.J. Barnes Am. J. Med. 117 2004 24S 32S
6. N.J. Gross Eur. J. Pharmacol. 533 2006 36
7. N.A. Hanania, and J.F. Donohue Proc. Am. Thorac. Soc. 4 2007 526
8. M. Prat, D. Fernández, M.A. Buil, M.I. Crespo, G. Casals, M. Ferrer, L. Tort, J. Castro, J.M. Monleón, A. Gavald, M. Miralpeix, I. Ramos, T. Doménech, D. Vilella, F. Antón, J.M. Huerta, E. Espinosa, M. López, S. Sentellas, M. González, J. Albertí, V. Segarra, A. Cárdenas, J. Beleta, and H. Ryder J. Med. Chem. 52 2009 5076
9. J. Nilsson, G. Lars, J. Wagermark, and R. Dahlbom Acta Pharm. Suecica 5 1968 71
10. J.A. Butera, and T.M. Argentieri Expert Opin. Ther. Pat. 8 1998 1017
11. D.P. Zlotos, W. Bender, and U. Holzgrabe Expert Opin. Ther. Pat. 9 1999 1029
12. N. Mealy, and J. Castañer Drugs Fut. 24 1999 871
13. Naito, R.; Takeuchi, M.; Morihira, K.; Hayakawa, M.; Ikeda, K.; Takemoto, T. Poster-2.28, 14th International Symposium on Medicinal Chemistry, Maastricht, The Netherlands, Sept 8-12, 1996; EFMC, IUPAC.
14. R. Naito, M. Takeuchi, K. Morihira, M. Hayakawa, K. Ikeda, T. Shibanuma, and Y. Isomura Chem. Pharm. Bull. 46 1998 1286
15. Drug Data Report. 1998, 20, 139.
16. Thomson Reuters Drug News (formerly Daily Drug News) June 8, 2006, Tolterodine tartrate, 154881.
17. D.I. Lainé Expert Rev. Clin. Pharmacol. 3 2010 43
18. J.A. Lieberman Prim. Care Companion J. Clin. Psychiatry. 6 2004 20
19. W. Vincken, J.A. van Noord, A.P.M. Greefhorst, A. Bantje, S. Kesten, L. Korducki, P.J.G. Cornelissen, J.M.M. van de Bosch, W.H. Dalinghaus, M.E. Eland, W.B.M. Evers, S.J.M. Gans, H.Ch. Gooszen, A.P.M. Greefhorst, A.J. van Harreveld, J.H.L.M. van Kasteren, A.F. Kuipers, G.D. Nossent, B.J.M. Pannekoek, H.R. Pasma, A. Peters, W.R. Pieters, P.E. Postmus, A.J.M. Schreurs, H.E.J. Sinninghe, A.P. Sips, P.I. van Spiegel, J. Westbroek, J.L. Aumann, E. Janssens, R. Pauwels, M. Radermecker, H. Slabbynck, I. Stappaerts, J. Verhaert, and P. Vermeire Eur. Respir. J. 19 2002 209
20. R. Casaburi, D.A. Mahler, P.W. Jones, A. Wanner, G. San Pedro, R.L. ZuWallack, S.S. Menjoge, C.W. Serby, and T. Witek Jr. Eur. Respir. J. 19 2002 217
21. G.B. Proctor J. Appl. Physiol. 100 2006 1103
22. T.A. Lee, A.S. Pickard, D.H. Au, B. Bartle, and K.B. Weiss Ann. Intern. Med. 149 2008 380
23. M. Saraswati, N. Lerner-Marmarosh, D.X. Wang, S.-S. Sheu, V. Sharma, and L.G. Abood Drug Dev. Res. 31 1994 142
24. 1) were determined as described in Ref. 8
25. Pharmacophore modelling and ligand preparation (3D conformations of the molecules were generated and ionized at pH = 7.4) were performed using Discovery Studio 2.5.5 environment (Accelrys Software Inc., San Diego CA)
26. H. Konzett, and R. Rössler Naunyn-Schmiedeberg's Arch. Exp. Pathol. Pharmacol. 195 1940 71
27. Values of duration of action were determined as described in Ref. 8.